4D Path Secures Funding and Adds Two New Board Members

4D Path is focused on developing digital biomarkers that help doctors choose more accurate cancer treatments earlier in the disease process. The company’s approach works across multiple cancer types, including breast, ovarian, colorectal and skin cancer. It has shown clinically meaningful results across different stages of disease and with both standard and investigational therapies like chemotherapy, and immunotherapy.

Katherine Vega Stultz brings decades of experience in strategy, clinical development, and commercializing healthcare therapies, including oncology treatments. She has served on the boards of both private and public companies. She will act as Board Chair for 4D Path.

Robert J. Hombach is a financial and operations leader with 30 years of experience in healthcare, having served on audit, finance, and compensation committees for multiple companies, including major public firms like BioMarin and Seaport Therapeutics.

Katherine Vega Stultz has led the launch of multiple multi-billion-dollar products and previously headed global clinical development at Celgene, where she managed more than 30 mid- and late-stage clinical programs in hematology and oncology. She is currently the CEO and President of BrainXell Therapeutics.

Robert J. Hombach previously served as Executive Vice President, CFO, and COO of Baxalta, a $6 billion global biopharma company, until its acquisition by Shire in 2016. He also played a key role in Baxalta’s spin-off from Baxter International, where he had earlier served as Corporate Vice President and CFO.

Read More:Vastian Announces Strategic Growth Investment from Bregal Sagemount

We are excited to add Katherine and Bob to our board. Katherine’s deep expertise in oncology strategy, R&D, and commercialization, coupled with Bob’s company strategy, financial and operational expertise, perfectly complements the outstanding group of leaders on our board,” said Jacopo Leonardi, CEO of 4D Path. “Their addition, coupled with our strategic financing, will serve as a catalyst to bring this promising treatment predictive technology one step closer to helping patients around the world beat cancer.”

“I am thrilled to be a part of the 4D Path growth story as the company embarks on further generating clinical evidence and advancing partnerships to identify better the most appropriate treatment approach for an individual patient. This is a critical unmet need for medical oncologists and a development challenge as companies progress their clinical strategies.”

"I am very excited to join the Board of 4D Path as the company builds a compelling growth trajectory of tremendous potential benefit for patients, providers, drug developers, and investors."

About 4D Path

Founded in 2016 by Satabhisa Mukhopadhyay and Tathagata Dasgupta, 4D Path has developed a platform called the Q-Plasia OncoReader that measures tumor behavior to help predict how patients will respond to cancer treatment, enabling more personalized therapy decisions and supporting both clinical care and research to improve cancer diagnosis and outcomes.

Read More:Altara Raises $7M in Seed Funding Led by Greylock